Humanizing Early Drug Discovery and Preclinical Safety Testing with Physiological iPS Cell Models
Recorded February 10, 2016
The recording of the webinar is available in full length here
Learn how human cardiac cells, derived from induced pluripotent stem cells (iPSC), are playing a rapidly increasing role in in vitro drug discovery & development assays in the pharmaceutical industry. From high-throughput screening (HTS) to toxicology testing, human cardiac cells can be applied in pure 2D cultures for desired controls as well as 3D co-culture systems for physiological relevance. Whether you are screening for new drug targets, or investigating drug effects on electrophysiology, contractility, or cardiac-specific toxicity, this seminar will provide insights for your own research.
Uses of iPSC-derived cell types in screening/safety applications
Humanize drug discovery/development, "Mimic Clinic"
'Real-world' examples / case studies
Axiogenesis background / overview, products/services
Thomas Licher, PhD
Group Leader Lead Identification Technologies (LIT) Biology
Andrew Bruening-Wright, PhD
Principal Scientist Discovery, Charles River
Ralf Kettenhofen, PhD
Head of Lab
Director Marketing & Sales